Metagenome and metabolism: The tissue microbiota hypothesis

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 61-70

  Burcelin, Rémy ^a,b   Serino, Matteo ^a,b   Chabo, Chantal ^a,b,c   Garidou, Lucile ^a,b   Pomié, Celine ^a,b   Courtney, Michael ^c   Amar, Jacques ^a,b,d   Bouloumié, Anne ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c VAIOMER SAS   (France)

^d CHU RANGUEIL   (France)

Author keywords

Brain axis; Diabetes; Gut; Inflammation; Obesity; Tissue microbiota

Indexed keywords

BACTERIAL DNA; LEPTIN; MYELOID DIFFERENTIATION FACTOR 88; SHORT CHAIN FATTY ACID; TRANSCRIPTOME;

ADIPOSE TISSUE; CALORIC RESTRICTION; FAT MASS; FOOD INTAKE; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; LIPID METABOLISM; METABOLIC PARAMETERS; METAGENOME; OBESITY; REVIEW; WEIGHT GAIN;

BRAIN AXIS; DIABETES; GUT; INFLAMMATION; OBESITY; TISSUE MICROBIOTA;

ANIMALS; CELL COMMUNICATION; HOST SPECIFICITY; HUMANS; INTESTINES; METABOLIC DISEASES; METABOLISM; METAGENOME; MICE; MICROBIOTA;

EID: 84883509271     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12157     Document Type: Review

References (106)

1. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
2. Bouloumie A, Casteilla L, Lafontan M. Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first? Arterioscler Thromb Vasc Biol 2008; 28: 1211-1213.
3. Amar J, Chabo C, Waget A et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3: 559-572.
4. Knoll AH, Barghoorn ES. Archean microfossils showing cell division from the swaziland system of South Africa. Science 1977; 198: 396-398.
5. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-712.
6. Nicholson JK, Holmes E, Kinross J et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.
7. Sagan L. On the origin of mitosing cells. J Theor Biol 1967; 14: 255-274.
8. Gray MW, Burger G, Lang BF. The origin and early evolution of mitochondria. Genome Biol 2001; 2: REVIEWS1018.
9. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920.
10. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
11. Hansen CH, Nielsen DS, Kverka M et al. Patterns of early gut colonization shape future immune responses of the host. PLoS One 2012; 7: e34043.
12. Palmer C, Bik EM, Digiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: e177.
13. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999; 69: 1035S-1045S.
14. Dethlefsen L, Eckburg PB, Bik EM, Relman DA. Assembly of the human intestinal microbiota. Trends Ecol Evol 2006; 21: 517-523.
15. Backhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011; 58(Suppl 2): 44-52.
16. Olszak T, An D, Zeissig S et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336: 489-493.
17. Round JL, O'Connell RM, Mazmanian SK. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010; 34: J220-225.
18. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-323.
19. Ivanov II, Frutos Rde L, Manel N et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008; 4: 337-349.
20. Sommer F, Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013; 11: 227-238.
21. Caesar R, Reigstad CS, Backhed HK et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut 2012; 61: 1701-1707.
22. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol 2010; 10: 735-744.
23. Burcelin R, Garidou L, Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin Immunol 2012; 24: 67-74.
24. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484.
25. Yatsunenko T, Rey FE, Manary MJ et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-227.
26. Azad MB, Konya T, Maughan H et al. Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4months. CMAJ 2013; 185: 385-394.
27. Smith MI, Yatsunenko T, Manary MJ et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013; 339: 548-554.
28. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230.
29. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011; 121: 5-9.
30. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
31. Membrez M, Blancher F, Jaquet M et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22: 2416-2426.
32. Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W, Fernandez-Real JM. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 2006; 55: 216-224.
33. Markle JG, Frank DN, Mortin-Toth S et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 2013; 339: 1084-1088.
34. Neufeld KA, Kang N, Bienenstock J, Foster JA. Effects of intestinal microbiota on anxiety-like behavior. Commun Integr Biol 2011; 4: 492-494.
35. Claesson MJ, Cusack S, O'Sullivan O et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011; 108(Suppl 1): 4586-4591.
36. Claesson MJ, Jeffery IB, Conde S et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488: 178-184.
37. Collino S, Montoliu I, Martin FP et al. Metabolic signatures of extreme longevity in northern italian centenarians reveal a complex remodeling of lipids, amino acids, and gut microbiota metabolism. PLoS One 2013; 8: e56564.
38. Rehman T. Role of the gut microbiota in age-related chronic inflammation. Endocr Metabol Immune Dis DrugTarg 2012; 12: 361-367.
39. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-15723.
40. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
41. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11070-11075.
42. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
43. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 2002; 282: E834-E42.
44. Serino M, Luche E, Gres S et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012; 61: 543-553.
45. Wu X, Ma C, Han L et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010; 61: 69-78.
46. Larsen N, Vogensen FK, van den Berg FW et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085.
47. Serino M, Fernandez-Real JM, Fuentes EG et al. The gut microbiota profile is associated with insulin action in humans. Acta Diabetol. 2012; DOI:10.1007/s00592-012-0410-5.
48. Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 2010; 21: 76-83.
49. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastronterol Hepatol 2010; 7: 691-701.
50. Henao-Mejia J, Elinav E et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
51. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609.
52. Le Cao KA, Rossouw D, Robert-Granie C, Besse P. A sparse PLS for variable selection when integrating omics data. Stat Appl Genet Mol Biol 2008; 7: Article 35.
53. Qin J, Li Y, Cai Z et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60.
54. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104: 979-984.
55. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997; 246: 259-273.
56. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
57. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
58. Feuerer M, Herrero L, Cipolletta D et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930-939.
59. Nishimura S, Manabe I, Nagasaki M et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15: 914-920.
60. Winer S, Paltser G, Chan Y et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009; 39: 2629-2635.
61. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668.
62. Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005; 8: 347-354.
63. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 1161: 115-124.
64. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
65. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
66. Amar J, Burcelin R, Ruidavets JB et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 1219-1223.
67. Laugerette F, Vors C, Geloen A et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011; 22: 53-59.
68. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90-97.
69. Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, van 't Veer C, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003; 170: 1399-405.
70. Yan YJ, Li Y, Lou B, Wu MP. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 2006; 79: 210-215.
71. Lee RP, Lin NT, Chao YF, Lin CC, Harn HJ, Chen HI. High-density lipoprotein prevents organ damage in endotoxemia. Res Nurs Health 2007; 30: 250-260.
72. Moreno-Navarrete JM, Manco M, Ibanez J et al. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int J Obes (Lond) 2010; 34: 240-249.
73. Lassenius MI, Pietilainen KH, Kaartinen K et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diab Care 2011; 34: 1809-1815.
74. Wellhoener P, Vietheer A, Sayk F, Schaaf B, Lehnert H, Dodt C. Metabolic alterations in adipose tissue during the early phase of experimental endotoxemia in humans. Horm Metab Res 2011; 43: 754-759.
75. Turnbaugh P, Ridaura V, Faith J, Rey F, Knight R, Gordon J. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Trans Med 2009; 1: 6-14.
76. Moreira AP, Texeira TF, Ferreira AB, Peluzio Mdo C, Alfenas RC. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 2012; 108: 801-809.
77. Caricilli AM, Picardi PK, de Abreu LL et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol 2011; 9: e1001212.
78. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One 2012; 7: e47713.
79. Ehses JA, Meier DT, Wueest S et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010; 53: 1795-1806.
80. Vijay-Kumar M, Aitken JD, Carvalho FA et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-231.
81. Vijay-Kumar M, Carvalho FA, Aitken JD, Fifadara NH, Gewirtz AT. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 2010; 40: 3528-3534.
82. Zu L, He J, Jiang H, Xu C, Pu S, Xu G. Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway. J Biol Chem 2009; 284: 5915-5926.
83. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y. Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 2007; 354: 45-49.
84. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
85. Poggi M, Bastelica D, Gual P et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007; 50: 1267-1276.
86. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006; 346: 739-745.
87. Purohit J, Hu P, Burke SJ, Collier JJ, Chen J, Zhao L. The effects of NOD activation on adipocyte differentiation. Obesity 2013; 21: 737-747.
88. Schertzer JD, Tamrakar AK, Magalhaes JG et al. NOD1 activators link innate immunity to insulin resistance. Diabetes 2011; 60: 2206-2215.
89. Cani PD, Possemiers S, Van de Wiele T et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103.
90. Sansonetti P. Host-pathogen interactions: the seduction of molecular cross talk. Gut 2002; 50(Suppl 3): III2-III8.
91. Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharm Res 2013; 69: 42-51.
92. Mann ER, Landy JD, Bernardo D et al. Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. Immunol Lett 2013; 150: 30-40.
93. Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013; 36: 305-312.
94. Pezzulo AA, Hornick EE, Rector MV et al. Expression of human paraoxonase 1 decreases superoxide levels and alters bacterial colonization in the gut of Drosophila melanogaster. PLoS One 2012; 7: e43777.
95. Marion-Letellier R, Raman M, Savoye G, Dechelotte P, Ghosh S. Nutrient modulation of autophagy: implications for inflammatory bowel diseases. Inflamm Bowel Dis 2013; 19: 205-212.
96. Porter EM, Bevins CL, Ghosh D, Ganz T. The multifaceted Paneth cell. Cell Mol Life Sci 2002; 59: 156-170.
97. Hosoi T, Yokoyama S, Matsuo S, Akira S, Ozawa K. Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of diabetes in mice. PLoS One 2010; 5: e12537.
98. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol 2007; 4: 1-13.
99. Amar J, Serino M, Lange C, Chabo C et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011; 54: 3055-3061.
100. Amar J, Lange C, Payros G et al. Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the d.e.s.I.R. Study. PLoS One 2013; 8: e54461.
101. Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010; 268: 320-328.
102. Koren O, Spor A, Felin J et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 2011; 108(Suppl 1): 4592-4598.
103. Blasco-Baque V, Serino M, Vergnes JN et al. High-fat diet induces periodontitis in mice through lipopolysaccharides receptor signaling: protective action of estrogens. PLoS One 2012; 7: e48220.
104. Hashimoto T, Perlot T, Rehman A et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487: 477-481.
105. Kaddurah-Daouk R, Baillie RA, Zhu H et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 2011; 6: e25482.
106. Sayin SI, Wahlstrom A, Felin J et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-235.